Cargando…
Targeting G(i/o) protein–coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy
GPCRs are highly desirable drug targets for human disease. Although GPCR dysfunction drives development and progression of many tumors, including breast cancer (BC), targeting individual GPCRs has limited efficacy as a cancer therapy because numerous GPCRs are activated. Here, we sought a new way of...
Autores principales: | Lyu, Cancan, Ye, Yuanchao, Lensing, Maddison M., Wagner, Kay-Uwe, Weigel, Ronald J., Chen, Songhai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492335/ https://www.ncbi.nlm.nih.gov/pubmed/34343132 http://dx.doi.org/10.1172/jci.insight.150532 |
Ejemplares similares
-
Blocking Gi/o-Coupled Signaling Eradicates Cancer Stem Cells and Sensitizes Breast Tumors to HER2-Targeted Therapies to Inhibit Tumor Relapse
por: Lyu, Cancan, et al.
Publicado: (2022) -
Active Gαi/o mutants accelerate breast tumor metastasis via the c-Src pathway
por: Lyu, Cancan, et al.
Publicado: (2023) -
The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009) -
The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021) -
Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
por: Yoshikawa, Ayumu, et al.
Publicado: (2022)